Payment overview · 2025
General Payments
$352.66
18 reported records · 12 companies
Healthcare provider profile · identity verified
Sandra Buchanan, MD
Allopathic & Osteopathic Physicians|Family Medicine · PORT ORANGE, FL · NPI 1003923731
Verified facts
What the public records show
CMS Open Payments records show Sandra Buchanan, MD received $352.66 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.75 | 23.2% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $47.87 | 13.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.43 | 12.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.77 | 11.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.91 | 7.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.09 | 5.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.65 | 5.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.40 | 4.9% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.13 | 4.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.72 | 4.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.23 | 4.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.71 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $352.66 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $47.87 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.42 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.33 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
99 | 25 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 615 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 474 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 428 | 122 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 389 | 108 |
| Losartan Potassium | Losartan Potassium | 349 | 107 |
| Lisinopril | Lisinopril | 347 | 102 |
| Ezetimibe | Ezetimibe | 260 | 75 |
| Omeprazole | Omeprazole | 256 | 72 |
| Gabapentin | Gabapentin | 235 | 57 |
| Eliquis | Apixaban | 197 | 45 |
| Metformin Hcl | Metformin Hcl | 195 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 56 |
| Alprazolam | Alprazolam | 147 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 42 |
| Famotidine | Famotidine | 137 | 48 |
| Trazodone Hcl | Trazodone Hcl | 136 | 39 |
| Furosemide | Furosemide | 134 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 34 |
| Carvedilol | Carvedilol | 118 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 30 |
| Tramadol Hcl | Tramadol Hcl | 114 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 29 |
| Meloxicam | Meloxicam | 107 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 39 |
| Potassium Chloride | Potassium Chloride | 102 | 31 |
| Simvastatin | Simvastatin | 102 | 29 |
| Synthroid | Levothyroxine Sodium | 99 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 25 |
| Montelukast Sodium | Montelukast Sodium | 88 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 24 |
| Prednisone | Prednisone | 85 | 33 |
| Allopurinol | Allopurinol | 82 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 25 |
| Lorazepam | Lorazepam | 82 | 28 |
| Alendronate Sodium | Alendronate Sodium | 80 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 20 |
| Spironolactone | Spironolactone | 80 | 23 |
| Azithromycin | Azithromycin | 77 | 58 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 53 |
| Sertraline Hcl | Sertraline Hcl | 68 | 18 |
| Farxiga | Dapagliflozin Propanediol | 67 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 17 |
| Atenolol | Atenolol | 62 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 62 | 16 |
| Amoxicillin | Amoxicillin | 61 | 37 |
| Azelastine Hcl | Azelastine Hcl | 60 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 14 |
| Pregabalin | Pregabalin | 48 | 13 |
| Estradiol | Estradiol | 47 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Acyclovir | Acyclovir | 43 | 14 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Glimepiride | Glimepiride | 40 | 11 |
| Cefuroxime | Cefuroxime Axetil | 37 | 31 |
| Diazepam | Diazepam | 37 | 11 |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Benazepril Hcl | Benazepril Hcl | 36 | 11 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 31 |
| Nitroglycerin | Nitroglycerin | 34 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 29 |
| Buspirone Hcl | Buspirone Hcl | 33 | 11 |
| Ibuprofen | Ibuprofen | 32 | 11 |
| Ramipril | Ramipril | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 11 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 16 |
| Valsartan | Valsartan | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Lactulose | Lactulose | 23 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Cephalexin | Cephalexin | 18 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Diovan | Valsartan | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $352.66 · 18 records | ABBVIE INC. | AIRSUPRA, AREXVY, CAPVAXIVE, Cologuard Collection Kit, ENTRESTO, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error